Seminars in Oncology
Volume 29, Issue 6 , Pages 546-551 , December 2002

Complementary and alternative medicine research: A National Cancer Institute perspective

References 

  1. Panel on Definition and Description CRMC, April 1995 . Defining and describing complementary and alternative medicine. Altern Ther Health Med. 1997;3:49–57
  2. National Center for Complementary and Alternative Medicine web site: http://nccam.nih.gov/nccam/fcp/classify/
  3. Congress OoTA US. Pharmacologic and Biologic Treatments. Unconventional Cancer Treatments, OTA-H-405. In: Washington, DC: US Government Printing Office; 1990;p. 102–107
  4. Moertel CG, Fleming TR, Rubin J, et al.  A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201–206
  5. Gonzalez NJ. Testimony at the White House Commission for Complementary and Alternative Medicine Policy. Washington, DC. October 5, 2000;
  6. McCombs DA. Testimony at the White House Commission for Complementary and Alternative Medicine Policy. Washington, DC 2000;
  7. Jonas WB, Linde K, Walach H. How to practice evidenced-based complementary and alternative medicine. In:  Jonas WB,  Levin JS editor. Essentials of Complementary and Alternative Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 72–87
  8. Buckner JC, Malkin MG, Reed E, et al.  Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc. 1999;74:137–145
  9. Burzynski S. Efficacy of Antineoplastons A10 and AS2-1. Mayo Clinic Proc. 1999;74:641–642 (letter)
  10. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer. 1998;83:777–782
  11. Sparber A, Wootton JC. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med. 2001;7:281–287
  12. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: A national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–1121
  13. Oneschuk D, Fennell L, Hanson J, et al.  The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care. 1998;14:21–26
  14. NCI Programs. Cancer Lett. 2000;26:6
  15. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer. 1999;33:117–124
  16. Sun AS, Ostadal O, Ryznar V, et al.  Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer. 1999;34:62–69
  17. Chlebowski RT, Bulcavage L, Grosvenor M, et al.  Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer. 1987;59:406–410
  18. Kosty MP, Herndon JE, Green MR, et al.  Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J Clin Oncol. 1995;13:1529–1530
  19. Loprinzi CL, Goldberg RM, Su JQ, et al.  Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994;12:1126–1129
  20. Moertel CG, Fleming TR, Creagan ET, et al.  High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312:137–141
  21. Creagan ET, Moertel CG, O'Fallon JR, et al.  Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301:687–690
  22. Hawkins MJ, Friedman MA. National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst. 1992;84:1699–1702
  23. Vanchieri C. Alternative therapies getting notice through Best Case Series Program. J Natl Cancer Inst. 2000;92:1558–1560
  24. Ben-Shabat S, Fride E, Sheskin T, et al.  An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353:23–31
  25. Stermitz FR, Lorenz P, Tawara JN, et al.  Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA. 2000;97:1433–1437

☆ Address reprint requests to Jeffrey D. White, MD, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, Executive Plaza North, Suite 102, Bethesda, MD 20892.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50317-1

doi: 10.1053/sonc.2002.50003

Seminars in Oncology
Volume 29, Issue 6 , Pages 546-551 , December 2002

Article Tools